SABCS

CDK4/6 Inhibitor Combos Miss Survival Goal in Metastatic Breast Cancer Subset

December 12th 2024, 8:43pm

Article

No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations during initial treatment for HR-positive, HER2-negative metastatic breast cancer.

Ultra-Sensitive ctDNA Testing Can Detect ctDNA in HR+ Breast Cancer

December 12th 2024, 7:00pm

Article

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

Time to Next Treatment Slightly Higher With Orserdu in Breast Cancer Subset

December 12th 2024, 4:00pm

Article

In certain patients with ESR1-mutant breast cancer, time to next treatment was slightly higher with Orserdu versus PFS in a phase 3 trial.

Older Patients With Early Breast Cancer May Have Worse Immune Side Effects

December 12th 2024, 1:55pm

Article

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune checkpoint inhibitors.

Imlunestrant-Based Therapy May Improve Survival Without Progression in Advanced Breast Cancer

December 11th 2024, 11:00pm

Article

Treatment with imlunestrant either with or without Verzenio was shown to improve progression-free survival in some with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Local Recurrence Lowered With Immediate Surgery in Elderly Patients With Breast Cancer

December 11th 2024, 10:30pm

Article

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Lynparza Continues to Benefit in BRCA1/2+, HER2- Breast Cancer

December 11th 2024, 9:30pm

Article

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Enhertu Improves Progression-Free Survival in HR+, HER2-Low/Ultralow Metastatic Breast Cancer

December 11th 2024, 8:34pm

Article

Data from the phase 3 DESTINY-Breast06 trial were presented during the 2024 San Antonio Breast Cancer Symposium.

Camizestrant Plus Kisqali May Be Safe, Effective in ER+/HER2- Breast Cancer

December 11th 2024, 4:22pm

Article

Findings from the phase 1 SERENA-1 study were presented at the 2024 San Antonio Breast Cancer Symposium.

Looking Ahead After Kisqali’s FDA Approval for Adjuvant Treatment of Early Breast Cancer

December 10th 2024, 9:57pm

Article

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant setting with early breast cancer.